Reto Guler is Senior Scientist in the Cytokines and Disease Research Group at the International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town component and an Associate Professor based in the Division of Immunology, IDM, University of Cape Town and an associate member of the Institute of Infectious Disease & Molecular Medicine (IDM). In 2003, he completed his training in Immunology with a PhD degree from the University of Geneva, Switzerland where he investigated the role of TNF and TNF related molecules in mycobacterial infection and inflammation. For this work he was awarded the Swiss TB award. He then subsequently joined UCT for his postdoctoral studies. His current research focuses on pathogen and host-directed drug therapy for tuberculosis. This includes the identification of statins and host non-coding RNAs as host-directed drug therapy for TB and the role of epigenetics in host immunity to TB. Dr. Guler is the coordinator of the international PravaTB consortium that recently received a prestigious 4.9 million Euro award from the European & Developing Countries Clinical Trials Partnership (EDCTP) to conduct a clinical trial investigating the use of statins to prevent chronic lung inflammation and potentially TB relapse. He is a member of the international FANTOM consortium on genome-wide transcriptome analysis. He further investigates minor groove binders as novel anti-mycobacterial agents and non-ionic surfactant vesicles as a drug delivery system for tuberculosis. His current work is supported by grants from the Swiss-South Africa Joint Research Programme, EDCTP and the BRICS multilateral joint science and technology research collaboration.